Growth hormone secretion promoter
Patent Information
- Application Number
- MYPI2025004488
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-27
- Filing Date
- 2024-03-26
- Publication Date
- 2024-09-27
AI Technical Summary
Current somatostatin analogs, used to treat hormone-related disorders, lack specificity in activating somatostatin receptor subtypes, particularly SSTR5, which is expressed in growth hormone-producing cells, leading to unclear effects on growth hormone secretion and potential unintended hormone stimulation, limiting their application in anti-diabetic, anti-obesity, or anti-NASH treatments.
Development of a highly selective SSTR5 antagonist that promotes growth hormone secretion without affecting other anterior pituitary hormones, such as follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and prolactin, thereby selectively enhancing growth hormone levels.
The SSTR5 antagonist effectively stimulates growth hormone secretion in humans, addressing growth hormone deficiencies and related diseases, including childhood short stature, Turner syndrome, and adult growth hormone deficiency, while minimizing side effects on other hormone secretions.
Smart Images

Figure PI2025004488_DRAWING_001 
Figure PI2025004488_DRAWING_002 
Figure PI2025004488_DRAWING_003
Abstract
Description
Growth hormone secretagogues
[0001] The present invention relates to embodiments of a growth hormone secretagogue, etc., which contain a somatostatin receptor subtype 5 (hereinafter sometimes abbreviated as "SSTR5") antagonist as an active ingredient, and is useful, for example, in the field of medicine.
[0002] Somatostatin is a peptide hormone secreted from the hypothalamus, pancreatic delta cells, gastrointestinal endocrine cells, etc., and inhibits the secretion of various hormones, such as growth hormone and adrenocorticotropic hormone, via five somatostatin receptors (SSTR1-5), which are seven-transmembrane G protein-coupled receptors. Currently, somatostatin analogues such as octreotide and pasireotide are clinically used to treat various symptoms associated with excessive hormone secretion, such as acromegaly and Cushing's disease. However, because existing somatostatin analogues exhibit binding affinity to all SSTR1-5 receptors, it is not entirely clear which SSTR is activated to suppress the secretion of various hormones. Of the five receptors, SSTR5 is a receptor primarily expressed in small intestinal endocrine cells and pancreatic beta cells, and it is known that somatostatin binding inhibits the secretion of gastrointestinal hormones, such as glucagon-like peptide-1 and peptide YY, as well as insulin. On the other hand, analysis using human pituitary tumor tissues has reported that SSTR5 is also expressed in various anterior pituitary hormone-producing cells, including growth hormone-producing cells. However, it has also been revealed that other SSTRs are also expressed in these cells, and the expression profiles of the receptors vary from cell to cell (Non-Patent Document 1). Although studies using cultured cells have suggested a relationship between SSTR5 and growth hormone secretion control, these studies have only demonstrated this possibility at the cellular level, and it remains unclear how SSTR5 functions in regulating the secretion of anterior pituitary hormones, including growth hormone, at the biological level (Non-Patent Document 2). Furthermore, although elevated blood levels of adrenocorticotropic hormone were observed in SSTR5 knockout mice, elevated blood levels of insulin-like growth factor 1, whose production is enhanced by growth hormone, were not observed, making it unclear whether SSTR5 antagonists exert a growth hormone secretion-enhancing effect (Non-Patent Document 3).Furthermore, as described above, SSTR5 has been reported to be expressed in various anterior pituitary hormone-producing cells, and therefore, there has been strong concern that SSTR5 antagonists may induce increased secretion of multiple anterior pituitary hormones, resulting in unintended side effects due to increased secretion of other hormones in addition to the intended growth hormone secretion-enhancing effect. Thus, although multiple SSTR5 antagonists have been reported to date (e.g., Patent Documents 1 to 22, Non-Patent Document 4), while each SSTR5 antagonist is described as being useful for anti-diabetic, anti-obesity, anti-NASH, etc., there is no description of their growth hormone secretion-promoting activity or of the diseases that may be improved by promoting growth hormone secretion as an applicable disease. Furthermore, there have been no reports to date of SSTR5 antagonists exhibiting growth hormone secretion-promoting activity in humans.
[0003] International Publication No. WO 2014 / 142363, International Publication No. WO 2015 / 052910, International Publication No. WO 2015 / 064083, International Publication No. WO 2010 / 056717, International Publication No. WO 2010 / 129729, International Publication No. WO 2011 / 146324, International Publication No. WO 2012 / 024183, International Publication No. WO 2016 / 205032, International Publication No. WO 2006 / 094682, International Publication No. WO 2006 / 128803, International Publication No. WO 2007 / 025897 International Publication No. WO 2007 / 110340, International Publication No. WO 2008 / 000692, International Publication No. WO 2008 / 019967, International Publication No. WO 2008 / 031735, International Publication No. WO 2008 / 122510, International Publication No. WO 2008 / 145524, International Publication No. WO 2008 / 148710, International Publication No. WO 2021 / 113362, International Publication No. WO 2021 / 113363, International Publication No. WO 2021 / 113368, International Publication No. WO 2023 / 125486
[0004] Journal of Molecular Endocrinology (2014), 53, R1-R19J Clin Endocrinol Metab, September, 2003, 88 (9): 4239-4245 Mol Endocrinol, January 2003, 17 (1): 93-106 European Journal of Medicinal Chemistry 264 (2024) 116017
[0005] An object of the present invention is to provide, as an embodiment thereof, a novel growth hormone secretagogue, etc. More specifically, an object of the present invention is to provide, as one of its specific embodiments, a growth hormone secretagogue containing a somatostatin receptor subtype 5 ("SSTR5") antagonist as an active ingredient.
[0006] Under these circumstances, the present inventors have conducted extensive research into the effects of somatostatin on the secretion of various hormones. As a result, as detailed in the Examples section below, in tests using highly selective SSTR5 antagonists, they have discovered that the drug has a clear growth hormone secretagogue effect in humans, while, surprisingly, not affecting the secretion of other anterior pituitary hormones to which somatostatin is thought to contribute, such as follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and prolactin. Based on this new finding, the present inventors have completed the present invention, in which SSTR5 antagonists have a growth hormone secretagogue effect and can be used for the prevention or treatment of diseases that are improved by promoting growth hormone secretion. The present invention will be described below with reference to specific embodiments. However, the present invention is not limited to these embodiments.
[0007] [1] A growth hormone secretagogue containing an SSTR5 antagonist as an active ingredient. [2] The growth hormone secretagogue according to [1] above, which is a preventive and / or therapeutic agent for a disease that is improved by the promotion of growth hormone secretion. [3] A method for preventing and / or treating a disease that is improved by the promotion of growth hormone secretion, comprising administering an effective amount of an SSTR5 antagonist to a human or animal in need thereof. [4] An SSTR5 antagonist used for the prevention and / or treatment of a disease that is improved by the promotion of growth hormone secretion. [5] Use of an SSTR5 antagonist for the manufacture of a medicament for the prevention and / or treatment of a disease that is improved by the promotion of growth hormone secretion. [6] The growth hormone secretagogue according to the above [2], the method for prevention and / or treatment according to [3], the SSTR5 antagonist according to [4], or the use of the SSTR5 antagonist according to [5], wherein the disease that can be improved by promoting growth hormone secretion is one or more diseases selected from pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in pediatric chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wound, age-related decrease in growth hormone secretion, and infertility. [7] The growth hormone secretagogue according to the above [2], the prophylactic and / or therapeutic method according to [3], the SSTR5 antagonist according to [4], or the use of the SSTR5 antagonist according to [5], wherein the disease to be improved by promoting growth hormone secretion is one or more diseases selected from pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in pediatric chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, and adult growth hormone deficiency. [8] The growth hormone secretagogue according to the above [1], which is a growth promoter for animals (preferably livestock animals and / or aquatic animals) (i.e., a growth promoter for animals (preferably livestock animals and / or aquatic animals) containing an SSTR5 antagonist as an active ingredient).[9] A method for promoting animal growth, comprising administering an effective amount of an SSTR5 antagonist to an animal (preferably a livestock animal and / or an aquatic animal) in need thereof.
[10] An SSTR5 antagonist used for promoting the growth of an animal (preferably a livestock animal and / or an aquatic animal).
[11] Use of an SSTR5 antagonist for producing a growth promoter for an animal (preferably a livestock animal and / or an aquatic animal).
[0008]
[12] SSTR5 antagonists are disclosed in WO 2014 / 142363, WO 2015 / 052910, WO 2015 / 064083, WO 2010 / 056717, WO 2010 / 129729, WO 2011 / 146324, WO 2012 / 024183, WO 2016 / 205032, WO 2006 / 094682, WO 2006 / 128803, WO 2007 / 025897 No. 2007 / 110340, WO 2008 / 000692, WO 2008 / 019967, WO 2008 / 031735, WO 2008 / 122510, WO 2008 / 145524, WO 2008 / 148710, WO 2021 / 113362, WO 2021 / 113363, WO 2021 / 113368, WO 2023 / 125486, and European the growth hormone secretagogue described in [1] above, the growth hormone secretagogue described in [2] above, the method for prevention and / or treatment of [3] above, the SSTR5 antagonist described in [4] above, use of the SSTR5 antagonist described in [5] above, the growth hormone secretagogue described in [8] above, the growth promotion method described in [9] above, the SSTR5 antagonist described in
[10] above, or use of the SSTR5 antagonist described in
[11] above, which is selected from the compounds described in Journal of Medicinal Chemistry 264 (2024) 116017 or salts thereof (preferably an SSTR5 selective antagonist);
[13] The SSTR5 antagonist is selected from the compounds and salts thereof described in WO 2015 / 052910 and WO 2015 / 064083 (preferably an SSTR5 selective antagonist), the growth hormone secretagogue described in [1] above, the growth hormone secretagogue described in [2] above, the preventive and / or therapeutic method described in [3] above, the SSTR5 antagonist described in [4] above, use of the SSTR5 antagonist described in [5] above, the growth hormone secretagogue described in [8] above, the growth promotion method described in [9] above, the SSTR5 antagonist described in
[10] above, or use of the SSTR5 antagonist described in
[11] above.
[14] The SSTR5 antagonist is selected from the group consisting of 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((2-cyclopropyl-5-ethoxy-2',4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, 1-(1-((6-cyclopropyl-2,4'-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, the growth hormone secretagogue according to [1] above, the growth hormone secretagogue according to [2] above, the method for prevention and / or treatment according to [3] above, the SSTR5 antagonist according to [4] above, use of the SSTR5 antagonist according to [5] above, the growth hormone secretagogue according to [8] above, the method for growth promotion according to [9] above, the SSTR5 antagonist according to
[10] above, or use of the SSTR5 antagonist according to
[11] above, which is selected from 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, and salts thereof.
[15] The growth hormone secretagogue according to [1] above, the growth hormone secretagogue according to [2] above, the method for prevention and / or treatment according to [3] above, the SSTR5 antagonist according to [4] above, use of the SSTR5 antagonist according to [5] above, the growth hormone secretagogue according to [8] above, the growth promotion method according to [9] above, the SSTR5 antagonist according to
[10] above, or use of the SSTR5 antagonist according to
[11] above, wherein the SSTR5 antagonist is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a salt thereof.
[0009] In the above embodiments
[12] to
[15] , the disease that can be improved by promoting growth hormone secretion is preferably one or more diseases selected from pediatric growth hormone deficiency dwarfism, Turner syndrome dwarfism, chondrodystrophy dwarfism, pediatric chronic renal failure dwarfism, Prader-Willi syndrome dwarfism, SGA dwarfism, Noonan syndrome dwarfism, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wound, age-related decreased growth hormone secretion, and infertility. More preferably, the disease that can be improved by promoting growth hormone secretion is one or more diseases selected from pediatric growth hormone deficiency dwarfism, Turner syndrome dwarfism, chondrodystrophy dwarfism, pediatric chronic renal failure dwarfism, Prader-Willi syndrome dwarfism, SGA dwarfism, Noonan syndrome dwarfism, and adult growth hormone deficiency.
[0010]
[16] The SSTR5 antagonist is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a salt thereof, and the disease that can be improved by promoting growth hormone secretion is one or more diseases selected from the group consisting of pediatric growth hormone deficiency dwarfism, Turner syndrome dwarfism, chondrodystrophy dwarfism, pediatric chronic renal failure dwarfism, Prader-Willi syndrome dwarfism, Noonan syndrome dwarfism, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wounds, age-related decreased growth hormone secretion, and infertility. Use of the growth hormone secretagogue described in [2] above, the preventive and / or therapeutic method described in [3] above, the SSTR5 antagonist described in [4] above, or the SSTR5 antagonist described in [5] above.
[17] The growth hormone secretagogue according to the above [2], the method for prevention and / or treatment according to [3], the SSTR5 antagonist according to [4], or use of the SSTR5 antagonist according to [5], wherein the SSTR5 antagonist is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a salt thereof, and the disease that can be improved by promoting growth hormone secretion is one or more diseases selected from pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in pediatric chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, and adult growth hormone deficiency.
[0011] The present invention provides, as an embodiment thereof, a novel growth hormone secretagogue, etc. More specifically, the present invention provides, as one specific embodiment thereof, a growth hormone secretagogue containing a somatostatin receptor subtype 5 ("SSTR5") antagonist as an active ingredient. The growth hormone secretagogue is expected to selectively exhibit a growth hormone secretagogue effect without substantially affecting the secretion of other anterior pituitary hormones involved in somatostatin (all or some of the following hormones: follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, prolactin, etc.).
[0012] Fig. 1 shows the change over time in blood growth hormone concentration, as evaluated in Example 3 described below. Fig. 2 shows the change over time in blood follicle-stimulating hormone concentration, as evaluated in Example 3 described below. Fig. 3 shows the change over time in blood luteinizing hormone concentration, as evaluated in Example 3 described below. Fig. 4 shows the change over time in blood thyroid-stimulating hormone concentration, as evaluated in Example 3 described below. Fig. 5 shows the change over time in blood adrenocorticotropic hormone concentration, as evaluated in Example 3 described below. Fig. 6 shows the change over time in blood prolactin concentration, as evaluated in Example 3 described below.
[0013] This specification discloses the above-mentioned embodiments, such as a growth hormone secretagogue containing an SSTR5 antagonist as an active ingredient, and the growth hormone secretagogue which is a preventive and / or therapeutic agent for diseases that are ameliorated by the promotion of growth hormone secretion; a method for preventing and / or treating diseases that are ameliorated by the promotion of growth hormone secretion, which comprises administering an effective amount of an SSTR5 antagonist to a human or animal in need thereof; an SSTR5 antagonist used for the prevention and / or treatment of diseases that are ameliorated by the promotion of growth hormone secretion; and use of an SSTR5 antagonist for the manufacture of a medicament for the prevention and / or treatment of diseases that are ameliorated by the promotion of growth hormone secretion.
[0014] The present invention will be described in detail below according to the embodiments, but unless otherwise specified, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.
[0015] (Regarding SSTR5 Antagonists) The somatostatin receptor is a seven-transmembrane G protein-coupled receptor, and five subtypes have been found to date, designated SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5. In this specification, the term "SSTR5 antagonist" refers to a general compound having an antagonistic effect on SSTR5. Many "SSTR5 antagonists" are already known in the art, and the term "SSTR5 antagonist" is recognized and widely used by those skilled in the art as a comprehensive technical term referring to this group of compounds. In embodiments of the present invention, a person skilled in the art can appropriately select a preferred SSTR5 antagonist from the viewpoints of efficacy, safety, etc. In particular, it is preferable to select an SSTR5 antagonist (an SSTR5-selective antagonist) having high selectivity for SSTR5 (SSTR5-selective antagonism) among the five SSTRs. Such SSTR5 antagonism and selectivity for SSTR5 can be confirmed according to methods known in the art.
[0016] Examples of such SSTR5 antagonists include those described in International Publication Nos. WO 2014 / 142363, WO 2015 / 052910, WO 2015 / 064083, WO 2010 / 056717, WO 2010 / 129729, WO 2011 / 146324, WO 2012 / 024183, WO 2016 / 205032, WO 2006 / 094682, WO 2006 / 128803, and WO 2007 / 02589. 7, WO 2007 / 110340, WO 2008 / 000692, WO 2008 / 019967, WO 2008 / 031735, WO 2008 / 122510, WO 2008 / 145524, WO 2008 / 148710, WO 2021 / 113362, WO 2021 / 113363, and WO 2021 / 113368, as well as WO 2023 / 125486, and European Journal of Medicinal Chemistry 264 (2024) 116017 compounds or salts thereof.
[0017] Among these, preferred specific compounds include 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid (the compound described in WO 2015 / 052910, Example 4) or a salt thereof, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid (the compound described in WO 2015 / 052910, Example 67), 6-(1-((2-cyclopropyl-5-ethoxy-2',4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid (compound described in WO 2015 / 052910, Example 35), 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid (compound described in WO 2015 / 052910, Example 74), 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid (compound described in WO 2015 / 064083, Example 44), 1-(1-((6-cyclopropyl-2,4'-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid (compound described in WO 2015 / 064083, Example 49), 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid2-dihydropyridine-4-carboxylic acid (compound described in WO 2015 / 064083, Example 50), 4-{8-[(2-(cyclopropyl)-5-trifluoromethylphenyl)methyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl}benzoic acid (compound described in WO 2012 / 024183, Examples 4-50), 6-{8-[(4-ethoxy-2',3',4'-trifluorobiphenyl-2-yl)methyl]-1-oxa-2,8-diazaspiro[4.5]dec-2-en-3-yl}pyridine-3-carboxylic acid (compound described in WO 2011 / 146324, Example 30), 4-[8-[(2-cyclopropyl-5-ethoxy-4-methyl-phenyl)methyl]-2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl]benzoic acid (compound described in WO 2016 / 205032, Example 1), N-[1-(2,6-diethoxy-4'-fluoro-biphenyl-4-ylmethyl)-piperidin-4-yl]-5-methyl-nicotinamide (compound described in WO 2006 / 128803, Example 153), 6-[1-(4-chloro-3,5-diethoxy-benzyl)-piperidin-4-ylamino]-nicotinic acid (compound described in WO 2008 / 019967, Example 70), and 4-(8-((2-cyclopropyl-5-ethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl)benzenesulfonic acid (compound described in WO 2021 / 113362, Example 1), in addition, 4-(7-(2-cyclopropyl-5-ethoxy-4-methylbenzyl)-2,7-diazaspiro[3.5]non-2-yl)-2-fluorobenzoic acid (compound described in WO 2023 / 125486, Example 34), and 4-(((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-4-fluoropiperidin-4-yl)methyl)amino)-2-methoxybenzoic acid (European Journal of Medicinal Chemistry 264 (2024) 116017, compound 23), or a salt thereof,
[0018] Furthermore, particularly preferred specific compounds include 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((2-cyclopropyl-5-ethoxy-2',4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, 1-(1-((6-cyclopropyl-2,4'-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, or a salt thereof,
[0019] The most preferred specific compound is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a salt thereof. The above-mentioned "SSTR5 antagonist" can be produced by a person skilled in the art by appropriately utilizing the methods described in the above-mentioned patent documents or methods known in the technical field, and can be used in the embodiments of the present invention.
[0020] As will be demonstrated using representative SSTR5 antagonists in the Examples section below, an "SSTR5 antagonist" exerts a desired growth hormone secretion-promoting effect based on its antagonism against SSTR5.
[0021] In embodiments of the present invention, the "SSTR5 antagonist" can be used in either its free form or its salt form (preferably, a pharmaceutically acceptable salt thereof). Those skilled in the art can carry out the present invention by appropriately selecting either form based on the characteristics of the individual SSTR5 antagonist used. Examples of pharmaceutically acceptable salts include salts with acids such as salts with inorganic acids (e.g., hydrochloride, hydrobromide, sulfate, phosphate), salts with organic acids (e.g., acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, tosylate, maleate), salts with bases (e.g., alkali metal salts (e.g., sodium salt, potassium salt), alkaline earth metal salts (e.g., calcium salt), salts with amino acids (e.g., glycine salt, lysine salt, arginine salt, ornithine salt, glutamate, aspartate), etc.
[0022] In an embodiment of the present invention, an SSTR5 antagonist can be used in the form of a prodrug. Those skilled in the art can design such a prodrug as appropriate, and the prodrug can be produced by a method known per se. The prodrug may be one that is converted into the desired SSTR5 antagonist under physiological conditions, as described in "Drug Development," Vol. 7, Molecular Design, pp. 163 to 198, Hirokawa Shoten, 1990.
[0023] (Uses) (1) Use as a Medicine After extensive research, the present inventors have found for the first time that SSTR5 antagonists exert an excellent growth hormone secretion-promoting effect due to their SSTR5 antagonism. Due to this growth hormone secretion-promoting effect, in diseases caused by growth hormone hyposecretion and / or diseases in which growth hormone is relatively deficient and can be expected to improve by its supplementation (e.g., diseases for which growth hormone replacement therapy is used), SSTR5 antagonists can promote growth hormone secretion from the pituitary gland and improve the pathology caused by growth hormone deficiency. Therefore, SSTR5 antagonists are useful for the prevention and / or treatment of diseases in humans or animals (particularly in humans) that can be improved by promoting growth hormone secretion. Examples of such diseases (particularly in humans) that can be improved by promoting growth hormone secretion include, but are not limited to, the following diseases or symptoms: (Examples of diseases) childhood growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in childhood chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wounds (e.g., trauma, burns, bedsores, diabetic foot lesions, etc.), age-related decreased secretion of growth hormone (e.g., age-related decreased bone mass, decreased muscle mass, increased body fat, abnormal lipid metabolism, fatty liver, easy fatigue, decreased concentration, decreased energy, emotional instability, dry / thinning skin, etc.), infertility; etc.In this embodiment, suitable conditions include: pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in pediatric chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wounds (e.g., trauma, burns, pressure ulcers, diabetic foot lesions, etc.), and age-related decreased secretion of growth hormone (e.g., age-related decreased bone mass, decreased muscle mass, increased body fat, abnormal lipid metabolism, fatty liver, fatigue, decreased concentration, decreased energy, emotional instability, dry and thinning skin, etc.), and more suitable conditions include: These include pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in childhood chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, and adult growth hormone deficiency.
[0024] As used herein, "prevention" includes preventing the onset of a disease (all pathologies or symptoms, or one or more pathologies or symptoms), and delaying the onset of the disease. A "prophylactically effective amount" refers to a dose of an SSTR5 antagonist sufficient to achieve this purpose. As used herein, "treatment" includes curing a disease (all pathologies or symptoms, or one or more pathologies or symptoms), ameliorating the disease, and inhibiting the progression of the severity of the disease. A "therapeutically effective amount" refers to a dose of an SSTR5 antagonist sufficient to achieve this purpose.
[0025] (2) Use as an Animal Growth Promoter As described above, the SSTR5 antagonist exhibits an excellent growth hormone secretion-promoting effect due to its SSTR5 antagonism, and therefore can also be used as an animal growth promoter (fattening agent, etc.).
[0026] (Regarding Administration Form) In an embodiment of the present invention, the SSTR5 antagonist can be used in either a single form or a pharmaceutical composition containing the SSTR5 antagonist as an active ingredient together with a pharmaceutically acceptable carrier.
[0027] Examples of such pharmaceutical compositions include tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules and microcapsules), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., immediate-release preparations, sustained-release preparations, sustained-release microcapsules), aerosols, films (e.g., orally disintegrating films, oral mucosal patch films), injections (e.g., subcutaneous injections, intravenous injections (e.g., bolus), intramuscular injections, intraperitoneal injections), drip infusions, transdermal preparations, ointments, lotions, patches, suppositories (e.g., rectal suppositories, vaginal suppositories), pellets, nasal preparations, pulmonary preparations (inhalants), and eye drops.
[0028] As used herein, the term "pharmaceutically acceptable carrier" refers to any of a variety of carriers commonly used in the field of pharmaceutical formulation technology.
[0029] Specific examples of "pharmaceutically acceptable carriers" that can be used in solid preparations include excipients (e.g., lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid, etc.), lubricants (e.g., magnesium stearate, talc, colloidal silica, etc.), binders (e.g., crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.), and disintegrants (e.g., starch, carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethylstarch, L-hydroxypropylcellulose, etc.).
[0030] Liquid preparations may contain solvents (e.g., water for injection, isotonic saline, alcohol, propylene glycol, macrogol, sesame oil, etc.), solubilizing agents (e.g., polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate, etc.), suspending agents (e.g., surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, etc.), isotonic agents (e.g., glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.), buffers (e.g., buffer solutions such as phosphates and citrates, etc.), and soothing agents (e.g., benzyl alcohol, etc.).
[0031] If necessary, formulation additives such as preservatives (e.g., paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, sorbic acid, etc.), antioxidants (e.g., sulfites, ascorbic acid, α-tocopherol, etc.), colorants, sweeteners, etc. may be further added.
[0032] The above pharmaceutical compositions may be prepared by adding an SSTR5 antagonist to the total formulation in an amount of typically 0.01 to 99% (w / w), preferably 0.1 to 85% (w / w), depending on the dosage form, administration method, carrier, etc. The pharmaceutical compositions may be prepared by conventional methods in the field of formulation technology depending on the form. The pharmaceutical compositions may also be formulated into controlled-release formulations, such as immediate-release or sustained-release formulations, containing the active ingredient.
[0033] When used as an animal growth promoter, the SSTR5 antagonist can be administered to animals in need thereof in the usual manner for animal breeding, but for example, the SSTR5 antagonist alone can also be administered by mixing it with animal feed or water.
[0034] The SSTR5 antagonists used in the embodiments of the present invention are expected to have low toxicity and few side effects, and also have excellent properties as pharmaceuticals. Therefore, the SSTR5 antagonists can be safely administered to humans or animals (e.g., livestock animals (cattle, pigs, horses, sheep, chickens, etc.), aquatic animals (tuna, sea bream, salmon, trout, yellowtail, pufferfish, grouper, etc.)), etc.) (particularly to humans).
[0035] (Regarding Administration Route) In an embodiment of the present invention, the SSTR5 antagonist may be administered alone or as a pharmaceutical composition orally or parenterally (e.g., intravenously, by infusion, intramuscularly, subcutaneously, intraorganically, intranasally, intradermally, transdermally, by instillation, intracerebrally, intrarectally, intravaginally, intraperitoneally, and into a lesion).
[0036] (Regarding Dosage) The dosage of the SSTR5 antagonist varies depending on the subject, route of administration, and age and symptoms of the subject, but is not particularly limited. Those skilled in the art can appropriately determine the dosage. For example, when administered to humans, the dosage is 0.1 to 320 mg, preferably 1 to 160 mg, of the SSTR5 antagonist active ingredient per oral administration. More preferred dosages include 1 to 80 mg (more specific dosages include, for example, 1 mg, 3 mg, 10 mg, 20 mg, 40 mg, or 80 mg; other specific dosages include, for example, 15 mg, 25 mg, 35 mg, or 75 mg). This dosage can be administered in 1 to 3 divided doses per day. Furthermore, when administered in the form of a sustained-release formulation, it can also be administered every other day or at intervals greater than this dosage.
[0037] (Regarding Combination with Other Drugs) In an embodiment of the present invention, an SSTR5 antagonist can be used in combination with other drugs to prevent or treat a target disease, and excellent preventive and / or therapeutic effects can be expected from the combination with other drugs. Furthermore, such combination therapy can be expected to reduce the dose of the other drug and thereby reduce the side effects of the other drug. Such combination with other drugs is also encompassed within the scope of the present invention. Drugs that can be used in combination with such SSTR5 antagonists (hereinafter sometimes abbreviated as "combined drugs") can be appropriately selected in consideration of the type of disease in the patient, the severity of the symptoms, etc. For example, concomitant use with growth hormone preparations (somatropin, somapsitan, somatorgon, lonapegsomatropin, PEG-somatropin, etc.), ghrelin mimetic agents (anamorelin, LUM-201, etc.), human C-type natriuretic peptide preparations (vosoritide, etc.), glucagon-like peptide-2 preparations (teduglutide, etc.), follicle-stimulating hormone preparations (follitropin alfa, corifollitropin alfa, etc.), minoxidil, or finasteride is possible. The administration form of the concomitant drug is not particularly limited, and the SSTR5 antagonist and the concomitant drug may be combined at the time of administration. For example, the present invention can be used in the following forms: (1) administration of a preparation containing a combination of an SSTR5 antagonist and a concomitant drug; (2) simultaneous or separate administration of two preparations obtained by separately formulating an SSTR5 antagonist and a concomitant drug via the same administration route; or (3) simultaneous or separate administration of two preparations obtained by separately formulating an SSTR5 antagonist and a concomitant drug via different administration routes. A preferred form can be appropriately selected depending on the actual situation in the medical field. The above-mentioned preparation containing a combination of an SSTR5 antagonist and a concomitant drug can be appropriately prepared by a person skilled in the art in accordance with the pharmaceutical composition containing an SSTR5 antagonist described above. The dosage of the concomitant drug can be appropriately selected based on the clinically used dose. Furthermore, the compounding ratio of the SSTR5 antagonist and the concomitant drug can be appropriately selected depending on the disease or symptoms of the subject, the administration route, the type of concomitant drug used, etc. Usually, the dosage can be appropriately determined based on the general clinical dose of the concomitant drug used in accordance with the actual situation in the medical field.
[0038] The following examples further illustrate the present invention in detail, but do not limit the scope of the present invention. Unless otherwise specified, the reagents, devices, and materials used in the present invention are commercially available or can be prepared by those skilled in the art.
[0039] Example 1: Evaluation of human SSTR5 antagonist activity using intracellular cAMP concentration as an index. Measurement of intracellular cAMP concentration was carried out using the HTRF cAMP dynamic 2 kit (Cisbio). Test compounds were diluted with assay buffer (5 mM HEPES (pH 7.5) (Invitrogen), 0.1% fatty-acid-free BSA (Sigma), 500 μM IBMX (Wako)-containing HBSS (Invitrogen)) and added at 2 μL / well to a 384-well white plate (Greiner) to a final concentration of 1 μM. A frozen stock of CHO (dhfr-) cells stably expressing the human SSTR5 gene (Accession No. NM_001053) was thawed in a 37°C incubator and suspended in a passage medium (MEM alpha (Wako)) containing 10% dialyzed serum (Gemini) and 50 μg / mL gentamicin (Invitrogen). After centrifugation of the cell suspension, the cells were resuspended in assay buffer and added at 2 μL to each well to achieve a concentration of approximately 4,000 cells / well. After incubating the cells with the compounds for 15 minutes, 2 μL / well of assay buffer containing 0.1 nM somatostatin 28 (Toray Research Center) and 0.3 μM forskolin (Wako) was added and incubated at room temperature for 30 minutes. 3 μL / well of cAMP-d2 and anti-cAMP-cryptate were added and incubated at room temperature for 60 minutes. Fluorescence resonance energy transfer (FRET) intensity was measured using a Multi-label reader Envision (Perkin Elmer). Using a calibration curve prepared from the FRET intensities of wells containing cAMP at various concentrations in the assay buffer, the FRET intensities of wells containing the test compounds were converted into cAMP concentrations. The inhibitory activity of the compounds was calculated using the following formula:Inhibitory activity (%) = (C - B) / (A - B) x 100 A: cAMP concentration calculated from wells to which 0.3 µM forskolin was added B: cAMP concentration calculated from wells to which 0.3 µM forskolin and 0.1 nM somatostatin 28 were added C: cAMP concentration in wells to which 0.3 µM forskolin, 0.1 nM somatostatin 28, and 1 µM test compound were added The inhibition rates (%) of SSTR5 at 1 µM of the test compounds are shown in Table 1.
[0040]
[0041]
[0042] As is clear from Table 1, the test compound exhibited excellent SSTR5 antagonistic activity.
[0043] Example 2 Evaluation of selectivity for human SSTR subtypes The selectivity of test compounds for human SSTR subtypes was examined by radioactively labeled ligand binding assay. Membrane fractions from CHO-K1 cells expressing human SSTR1-5 were diluted in assay buffer (25 mM HEPES (pH 7.4), 5 mM MgCl 2 , 1 mM CaCl 2 , 10 μg / mL saponin, 0.5% fatty-acid-free BSA), and 1 μM of test compound 1 and [ 125 I]Tyr 11 The membrane fraction was then transferred onto a filter plate, and the filter was washed with wash buffer (25 mM HEPES, 5 mM MgCl 2 , 1 mM CaCl 2 After washing six times with 50 μL of Microscint 20 (Packard), 50 μL of Microscint 20 (Packard) was added, and radioactivity was measured using a TopCount (Perkin Elmer). The results of the competitive activity of the test compounds against the binding of human SSTR subtypes to the labeled ligand are shown in Table 2.
[0044]
[0045] As is clear from Table 2, test compound 1 was shown to selectively bind to SSTR5 among human SSTR subtypes.
[0046] As shown in Example 3 below, test compound 1 exhibits an excellent growth hormone secretion-promoting effect. For this reason, as mentioned above, it is considered preferable to use an antagonist with high selectivity for SSTR5 (an SSTR5-selective antagonist) when practicing the present invention. The desired degree of selectivity for SSTR5 varies depending on the specific compound used and cannot be uniformly determined. However, a person skilled in the art can appropriately select a compound using, as a guideline, the fact that the compound has substantially no effect on other SSTRs at a dose that exhibits the desired antagonistic effect on SSTR5. The degree of selectivity for human SSTR subtypes can be evaluated, for example, by the method described in Example 2.
[0047] Example 3: Evaluation of Growth Hormone Secretion-Enhancing Effect of Test Compound 1 in Humans by Single Administration. This example shows the results of measuring blood anterior pituitary hormone concentrations using blood samples from a dose-escalation study in healthy Japanese adult males, part of a Phase 1 randomized, double-blind, placebo-controlled study (jRCT2051210027) conducted in healthy adult subjects to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of Test Compound 1. Study Overview: In a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study consisting of seven cohorts, subjects were administered a single oral dose of Test Compound 1 (1, 3, 10, 20, 40, 80, or 160 mg) or placebo under fasting conditions. Each cohort included eight subjects (six in the active drug group and two in the placebo group). Concomitant use of all medications was prohibited from 28 days prior to admission until discharge. Inclusion criteria: Patients must be between 20 and 45 years old at the time of consent, weigh 50 kg or more, and have a BMI of 18.5-25.0 kg / m 2Healthy Japanese adult males (both parents and grandparents of the subjects are Japanese) within the above range. Exclusion Criteria: Subjects with cardiovascular disease, central nervous system disease, digestive system disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, severe allergy, asthma, hypoxemia, hypertension, convulsions, or allergic rash at the time of this clinical trial. Subjects with abnormal laboratory values suggestive of a clinically significant disease at screening. Study Schedule: Subjects were examined and tested within 28-2 days and one day prior to administration of Test Compound 1, and eligibility was confirmed based on the above inclusion and exclusion criteria. Subjects who met all inclusion criteria and did not violate the exclusion criteria were randomized and orally administered Test Compound 1 (1, 3, 10, 20, 40, 80, or 160 mg) at 9:00 AM at the clinical trial medical institution. Subjects were fasted for 10 hours before administration and for 4 hours after administration until lunch, and lunch was consumed at 1:00 PM. Blood samples were taken 0.5 hours before administration and 1, 2, 4, 6, 8, and 10 hours after administration of Test Compound 1. Measurement of Blood Hormone Concentrations Anterior pituitary hormone concentrations were measured using blood from the placebo-administered group of all cohorts and subjects administered 1 mg or 10 mg of Test Compound 1 at 0.5 hours before administration and 2, 4, 6, 8, and 10 hours after administration. Blood growth hormone, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and prolactin concentrations were measured using the Human Growth Hormone Quantikine ELISA Kit (R&D Systems), the Follicle-Stimulating Hormone (Human) ELISA Kit (Cayman Chemical), the Luteinizing Hormone (Human) ELISA Kit (Cayman Chemical), the U-TSH ELISA (BIOCHECK), the ACTH ELISA Kit (MB Biosciences GmbH), and the Human Prolactin Quantikine ELISA Kit (Mitsubishi Biosciences GmbH), respectively. Measurements were performed using an ELISA kit (manufactured by R&D Systems) according to the protocol described in the attached instructions for each kit. Results The time course of the anterior pituitary hormone concentrations in blood after oral administration of placebo (n=14) or test compound 1 at doses of 1 mg and 10 mg (n=6 each) is shown in Figures 1 to 6.As is clear from Figures 1 to 6, Test Compound 1 was shown to exhibit a clear growth hormone secretion-enhancing effect in humans. These test results clearly demonstrate that Test Compound 1 and SSTR5 antagonists represented by Test Compound 1 are useful for the prevention and / or treatment of diseases that are improved by promoting growth hormone secretion.
[0048] Furthermore, Test Compound 1 did not substantially affect the secretion of other anterior pituitary hormones in which somatostatin is involved, such as follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and prolactin. This indicates that Test Compound 1 and SSTR5 antagonists typified by Test Compound 1 can be expected to selectively promote the secretion of growth hormone without affecting the secretion of all or part of anterior pituitary hormones such as follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, and prolactin.
[0049] In clinical practice, for example, external supplementation of growth hormone (growth hormone replacement therapy) has been used to treat diseases caused by growth hormone hyposecretion and / or a relative deficiency, and has been shown to be effective. The above clinical trial results demonstrate that Test Compound 1, a representative SSTR5 antagonist, clearly has the effect of promoting growth hormone secretion in humans. Furthermore, it has been confirmed that the increase in blood growth hormone concentration induced by Test Compound 1 is equivalent to the blood growth hormone concentration obtained by growth hormone replacement therapy in pediatric patients with short stature due to growth hormone deficiency (J Clin Endocrinol Metab. 2017, 102(5):1578-1587). This clearly demonstrates that SSTR5 antagonists are effective in treating diseases for which growth hormone replacement therapy is used, such as pediatric growth hormone deficiency dwarfism, Turner syndrome, chondrodystrophy, pediatric chronic renal failure, Prader-Willi syndrome, SGA dwarfism, Noonan syndrome, and adult growth hormone deficiency, as well as cancer cachexia, short bowel syndrome, alopecia, skin wounds, age-related decreased growth hormone secretion, infertility, and other conditions for which growth hormone replacement leads to improvement in the pathology and symptoms. Those skilled in the art can easily understand the "disease effect" exerted by such SSTR5 antagonists based on the status of disease treatment in clinical practice and the above-mentioned clinical trial results.
[0050] Furthermore, in livestock animals, external growth hormone supplementation is also performed in the hope of promoting their growth. Therefore, the above test results for Test Compound 1 clearly demonstrate that the administration of an SSTR5 antagonist to livestock animals and aquatic animals can also be expected to promote the growth of the animals due to its growth hormone secretion action. The effects of this SSTR5 antagonist can be easily understood by those skilled in the art.
[0051] The present invention provides a growth hormone secretagogue and the like, which is useful, for example, in the field of medicine.
[0052] This application is based on patent application No. 2023-049987 filed in Japan (filing date: March 27, 2023), the contents of which are incorporated in their entirety herein.
Claims
1. A growth hormone secretagogue containing an SSTR5 antagonist as an active ingredient.
2. The growth hormone secretion promoter according to claim 1, which is a preventive and / or therapeutic agent for diseases which are improved by promoting growth hormone secretion.
3. The growth hormone secretion promoter according to claim 2, wherein the disease which is improved by promoting growth hormone secretion is one or more diseases selected from the group consisting of pediatric growth hormone deficiency dwarfism, Turner syndrome dwarfism, chondrodystrophy dwarfism, pediatric chronic renal failure dwarfism, Prader-Willi syndrome dwarfism, Noonan syndrome dwarfism, adult growth hormone deficiency, cancer cachexia, short bowel syndrome, alopecia, skin wounds, decreased growth hormone secretion due to aging, and infertility.
4. The growth hormone secretion promoter described in claim 2, wherein the disease that is improved by promoting growth hormone secretion is one or more diseases selected from pediatric growth hormone deficiency dwarfism, short stature in Turner syndrome, short stature in chondrodystrophy, short stature in pediatric chronic renal failure, short stature in Prader-Willi syndrome, SGA dwarfism, short stature in Noonan syndrome, and adult growth hormone deficiency.
5. The growth hormone secretagogue according to claim 1, which is a growth promoter for animals.
6. The SSTR5 antagonist is disclosed in WO 2014 / 142363, WO 2015 / 052910, WO 2015 / 064083, WO 2010 / 056717, WO 2010 / 129729, WO 2011 / 146324, WO 2012 / 024183, WO 2016 / 205032, WO 2006 / 094682, WO 2006 / 128803, WO 2007 / 025897, WO 2007 / 110340, WO 2008 / 000692, WO 2008 / 019967, WO 2008 / 031735, WO 2008 / 122510, WO 2008 / 145524, WO 2008 / 148710, WO 2021 / 113362, WO 2021 / 113363, WO 2021 / 113368, WO 2023 / 125486, and European The growth hormone secretagogue according to any one of claims 1 to 5, which is selected from the compounds or salts thereof described in Journal of Medicinal Chemistry 264 (2024) 116017.
7. A growth hormone secretagogue according to any one of claims 1 to 5, wherein the SSTR5 antagonist is selected from the compounds and salts thereof described in WO 2015 / 052910 and WO 2015 / 064083.
8. The SSTR5 antagonist is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((2-cyclopropyl-5-ethoxy-2',4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 6-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid, 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, 1-(1-((6-cyclopropyl-2,4'-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, 6. The growth hormone secretagogue according to claim 1, which is selected from the group consisting of 1-(1-((6-cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, and salts thereof.
9. A growth hormone secretagogue according to any one of claims 1 to 5, wherein the SSTR5 antagonist is 6-(1-((2-cyclopropyl-5-ethoxy-4'-fluorobiphenyl-4-yl)methyl)piperidin-4-yl)-5-oxo-2-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a salt thereof.
10. A method for preventing and / or treating a disease that is ameliorated by promoting growth hormone secretion, comprising administering an effective amount of an SSTR5 antagonist to a human or animal in need thereof.
11. An SSTR5 antagonist used for the prevention and / or treatment of a disease that is improved by promoting growth hormone secretion.
12. Use of an SSTR5 antagonist for the manufacture of a medicament for the prevention and / or treatment of a disease that is improved by promoting growth hormone secretion.
13. A method for promoting growth in an animal, comprising administering to an animal in need thereof an effective amount of an SSTR5 antagonist.
14. SSTR5 antagonists used for growth promotion in animals.
15. Use of an SSTR5 antagonist for the manufacture of an animal growth promoter.
